267 related articles for article (PubMed ID: 12690476)
1. Prophylactic thyroidectomy in multiple endocrine neoplasia: the impact of molecular mechanisms of RET proto-oncogene.
Frilling A; Weber F; Tecklenborg C; Broelsch CE
Langenbecks Arch Surg; 2003 Mar; 388(1):17-26. PubMed ID: 12690476
[TBL] [Abstract][Full Text] [Related]
2. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
Marsh DJ; Mulligan LM; Eng C
Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
[TBL] [Abstract][Full Text] [Related]
3. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
Sansó G; Domené HM; Iorcansky S; Barontini M
Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
[TBL] [Abstract][Full Text] [Related]
4. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.
Frilling A; Dralle H; Eng C; Raue F; Broelsch CE
Surgery; 1995 Dec; 118(6):1099-103; discussion 1103-4. PubMed ID: 7491529
[TBL] [Abstract][Full Text] [Related]
5. Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group.
Frank-Raue K; Höppner W; Frilling A; Kotzerke J; Dralle H; Haase R; Mann K; Seif F; Kirchner R; Rendl J; Deckart HF; Ritter MM; Hampel R; Klempa J; Scholz GH; Raue F
J Clin Endocrinol Metab; 1996 May; 81(5):1780-3. PubMed ID: 8626834
[TBL] [Abstract][Full Text] [Related]
6. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG-->ATG) mutation.
Feldman GL; Edmonds MW; Ainsworth PJ; Schuffenecker I; Lenoir GM; Saxe AW; Talpos GB; Roberson J; Petrucelli N; Jackson CE
Surgery; 2000 Jul; 128(1):93-8. PubMed ID: 10876191
[TBL] [Abstract][Full Text] [Related]
7. Identification of multiple endocrine neoplasia, type 2 gene carriers using linkage analysis and analysis of the RET proto-oncogene.
Tsai MS; Ledger GA; Khosla S; Gharib H; Thibodeau SN
J Clin Endocrinol Metab; 1994 May; 78(5):1261-4. PubMed ID: 7909818
[TBL] [Abstract][Full Text] [Related]
8. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.
Eng C; Clayton D; Schuffenecker I; Lenoir G; Cote G; Gagel RF; van Amstel HK; Lips CJ; Nishisho I; Takai SI; Marsh DJ; Robinson BG; Frank-Raue K; Raue F; Xue F; Noll WW; Romei C; Pacini F; Fink M; Niederle B; Zedenius J; Nordenskjöld M; Komminoth P; Hendy GN; Mulligan LM
JAMA; 1996 Nov; 276(19):1575-9. PubMed ID: 8918855
[TBL] [Abstract][Full Text] [Related]
9. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship.
Yip L; Cote GJ; Shapiro SE; Ayers GD; Herzog CE; Sellin RV; Sherman SI; Gagel RF; Lee JE; Evans DB
Arch Surg; 2003 Apr; 138(4):409-16; discussion 416. PubMed ID: 12686527
[TBL] [Abstract][Full Text] [Related]
10. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma.
Hofstra RM; Landsvater RM; Ceccherini I; Stulp RP; Stelwagen T; Luo Y; Pasini B; Höppener JW; van Amstel HK; Romeo G
Nature; 1994 Jan; 367(6461):375-6. PubMed ID: 7906866
[TBL] [Abstract][Full Text] [Related]
11. Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations.
Fitze G; Schierz M; Bredow J; Saeger HD; Roesner D; Schackert HK
Ann Surg; 2002 Nov; 236(5):570-5. PubMed ID: 12409662
[TBL] [Abstract][Full Text] [Related]
12. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC.
Eng C; Smith DP; Mulligan LM; Healey CS; Zvelebil MJ; Stonehouse TJ; Ponder MA; Jackson CE; Waterfield MD; Ponder BA
Oncogene; 1995 Feb; 10(3):509-13. PubMed ID: 7845675
[TBL] [Abstract][Full Text] [Related]
13. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
[TBL] [Abstract][Full Text] [Related]
14. Novel point mutation in exon 10 of the RET proto-oncogene in a family with medullary thyroid carcinoma.
Oriola J; Páramo C; Halperin I; García-Mayor RV; Rivera-Fillat F
Am J Med Genet; 1998 Jul; 78(3):271-3. PubMed ID: 9677065
[TBL] [Abstract][Full Text] [Related]
15. Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating low grade malignancy.
Siggelkow H; Melzer A; Nolte W; Karsten K; Hoppner W; Hufner M
Eur J Endocrinol; 2001 May; 144(5):467-73. PubMed ID: 11331212
[TBL] [Abstract][Full Text] [Related]
16. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.
Frank-Raue K; Raue F
Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387
[TBL] [Abstract][Full Text] [Related]
17. RET proto-oncogene mutations are restricted to codon 634 and 618 in Korean families with multiple endocrine neoplasia 2A.
Chung YJ; Kim HH; Kim HJ; Min YK; Lee MS; Lee MK; Kim KW; Ki CS; Kim JW; Chung JH
Thyroid; 2004 Oct; 14(10):813-8. PubMed ID: 15588376
[TBL] [Abstract][Full Text] [Related]
18. Multiple endocrine neoplasia, the old and the new: a mini review.
Pasquali D; Di Matteo FM; Renzullo A; Accardo G; Esposito D; Barbato F; Colantuoni V; Circelli L; Conzo G
G Chir; 2012; 33(11-12):370-3. PubMed ID: 23140918
[TBL] [Abstract][Full Text] [Related]
19. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.
Donis-Keller H; Dou S; Chi D; Carlson KM; Toshima K; Lairmore TC; Howe JR; Moley JF; Goodfellow P; Wells SA
Hum Mol Genet; 1993 Jul; 2(7):851-6. PubMed ID: 8103403
[TBL] [Abstract][Full Text] [Related]
20. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations.
Learoyd DL; Gosnell J; Elston MS; Saurine TJ; Richardson AL; Delbridge LW; Aglen JV; Robinson BG
Clin Endocrinol (Oxf); 2005 Dec; 63(6):636-41. PubMed ID: 16343097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
